Patient P-02559

Synthetic patientMETA-24 · Day 141 · 25–34 · F · baseline S18Steering view · 3D Open companion preview

Therapy response

Stable

Tolerance

Deteriorating

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

86%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S18
Day 21 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 65 SC-12 recommended — Supportive Compound SC-12
Day 66 Patient accepted — Started SC-12 in the companion
Day 72 No meaningful change — Supportive Compound SC-12
Day 83 ME-01 recommended — Monitoring Escalation ME-01
Day 84 Patient accepted — Started ME-01 in the companion
Day 87 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 21.

Primary contributors, last 14 days

Toxicity+14
Inflammatory activity+12
Nutritional resilience-4
Treatment adherence-3

What helped?

Supportive Compound SC-12Day 65
Result: no meaningful change
Monitoring Escalation ME-01Day 83
Result: deterioration detected before clinical escalation

LIFE OS recommendation

GI Support Protocol GI-04

90%

probability of meaningful tolerance improvement

284 similar trajectories
88% showed improvement
median effect visible after 8 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes

Wearable

41 min

worsening · -2.6 vs previous 14 d

Sleep duration

Wearable

7.1 h

stable · -0.1 vs previous 14 d

Energy level

Daily log

2.7/10

stable · +0.1 vs previous 14 d

Steps

Wearable

3,739

stable · -52 vs previous 14 d

GI burden

Companion

59.5/100

improving · -6.3 vs previous 14 d

Adherence

Companion

40.7 %

worsening · -6.6 vs previous 14 d

Sleep quality

Wearable

52.3/100

stable · +0.7 vs previous 14 d

Glucose, CGM daily mean

CGM

136 mg/dL

stable · -2.3 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 26 from the failing basin, 64 from restoration.

Would help

GI-04 GI Support Protocol
75% improved among 65 similar · onset 8 d · confidence 89%
NP-02 Dietary Support Protocol
59% improved among 32 similar · onset 10 d · confidence 74%
CR-01 Clinician Review
100% improved among 6 similar · onset 5 d · confidence 74%
More protein
GI -5.7 next day on high-intake days · n 17

Would not help

SC-12 Supportive Compound
already tried, no meaningful change
Keep fibre low
GI +5.9 next day on high-intake days · n 13
Keep fat low
GI +5.6 next day on high-intake days · n 19
Keep histamine low
GI +5.4 next day on high-intake days · n 17

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Insoluble fibre
+5.9detractor · 95%
Protein
-5.7supporter · 95%
Dietary fat load
+5.6detractor · 95%
Histamine load
+5.4detractor · 95%
Ultra-processed food
+3detractor · 66%
Alcohol
+1.5no signal · 25%
Simple carbohydrates
-1.2no signal · 25%
Caffeine
-0.1no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 60 and rising
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 26/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↑70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 60
Drug metabolism and exposure ↑20
- BloodToxicity index 57
Autonomic recovery ↓20
- Wearable3,739 steps/day

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Intermediate metabolizer
Expected exposure
GLP1R rs6923761 A
Altered receptor sensitivity
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 3.2 · butyrate capacity 26/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 49 ms
Sleep: 7.2 h
Steps: 5,496
Resting HR: 66 bpm

Daily log: GI score 60, nutritional resilience 37, adherence 41.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02170	18%	S04	—	—	80
P-02048	19%	S02	—	—	77
P-02115	20%	S14	GI-04	improved	75
P-02575	21%	S14	ME-01	improved	73
P-02335	18%	S04	—	—	70
P-02550	19%	S01	—	—	70
P-02192	18%	S05	—	—	69
P-02659	22%	S09	—	—	69
P-02293	18%	S15	HY-01	no change	68
P-02591	30%	S13	—	—	68
P-02090	18%	S04	—	—	68
P-02265	28%	S07	GI-04	no change	67